Principal Investigator: Eric Sherman, MD and Nancy Lee, MD
Primary Objective:
To evaluate the safety of IMRT, paclitaxel, and pazopanib suspension
To evaluate and compare overall survival at 1 year from study registration.
Patient Population:
Pathologically (histologically or cytologically) proven diagnosis of anaplastic thyroid cancer (a diagnosis that is noted to be "consistent with anaplastic thyroid cancer" with the presence of a thyroid mass is acceptable)
The Phase II Component is open to accrual.
